Document Detail


How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?
MedLine Citation:
PMID:  20613629     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
An increasing number of patients in the community are being treated with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and beta-blockers for hypertension, coronary disease or diabetic renal and vascular complications. Some of these patients will develop heart failure despite such treatment. Based on data from hypertension trials it can be estimated that approximately 5% of treated patients will develop heart failure over 5 years. It is unclear whether patients developing heart failure on and off ACE-inhibitors or beta-blockers, respectively, at the time of heart failure diagnosis have similar prognosis.Treatment options for patients developing heart failure while already treated with ACE inhibitors/ARBs and beta-blockers are very limited if current heart failure guidelines are followed. In this review possible strategies are outlined and important areas for research are identified. It is suggested that trials are designed specifically to address prognosis and treatment in this growing population.
Authors:
Finn Gustafsson; Julian Segura; Luis M Ruilope
Related Documents :
22100929 - Effect of right ventricular pacing site on qrs width.
21738449 - Cardiac complications in patients with community-acquired pneumonia: a systematic revie...
22577429 - Chlamydia pneumoniae infection and cardiac risk factors in patients with myocardial inf...
22394459 - Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patie...
22560269 - A case of spontaneous coronary artery dissection: it is not always plaque rupture.
22110019 - Galectin-3 and the development of heart failure after acute coronary syndrome: pilot ex...
16390019 - Cold infarction areas of varying size in the presence of left ventricular dysfunction: ...
12417359 - Stroke vs. chronic progressive cerebrovascular disease: a magnetic resonance imaging st...
24553389 - High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of hypertension     Volume:  28     ISSN:  1473-5598     ISO Abbreviation:  J. Hypertens.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-21     Completed Date:  2010-11-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8306882     Medline TA:  J Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  1595-8     Citation Subset:  IM    
Affiliation:
Department of Cardiology, University of Copenhagen, Denmark bHypertension Unit, Hospital 12 de Octubre, Rigshospitalet, Madrid, Spain. finng@dadlnet.dk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use*
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Coronary Artery Disease / complications,  diagnosis,  drug therapy*
Diabetes Complications / diagnosis,  prevention & control*
Disease Progression
Heart Failure / etiology,  prevention & control*
Humans
Hypertension / complications,  diagnosis,  drug therapy*
Prognosis
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experiment...
Next Document:  Neuroretinitis with retrobulbar involvement.